Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MRVI 
Maravai Lifesciences Holdings Inc (MRVI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: MRVI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -35.04% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 734.34M USD | Price to earnings Ratio - | 1Y Target Price 5.06 |
Price to earnings Ratio - | 1Y Target Price 5.06 | ||
Volume (30-day avg) 1762162 | Beta 0.25 | 52 Weeks Range 1.67 - 10.03 | Updated Date 06/19/2025 |
52 Weeks Range 1.67 - 10.03 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.17 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-05-23 | When After Market | Estimate -0.02 | Actual -0.02 |
Profitability
Profit Margin -67.28% | Operating Margin (TTM) -78.39% |
Management Effectiveness
Return on Assets (TTM) -4.64% | Return on Equity (TTM) -44.32% |
Valuation
Trailing PE - | Forward PE 370.37 | Enterprise Value 374957628 | Price to Sales(TTM) 3.04 |
Enterprise Value 374957628 | Price to Sales(TTM) 3.04 | ||
Enterprise Value to Revenue 1.55 | Enterprise Value to EBITDA 1.77 | Shares Outstanding 143975008 | Shares Floating 92748977 |
Shares Outstanding 143975008 | Shares Floating 92748977 | ||
Percent Insiders 9.68 | Percent Institutions 89.91 |
Analyst Ratings
Rating 3.85 | Target Price 5.06 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 7 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Maravai Lifesciences Holdings Inc
Company Overview
History and Background
Maravai Lifesciences Holdings Inc. was founded in 2014. It quickly grew through strategic acquisitions and organic growth to become a leading provider of life science reagents and services to biopharmaceutical companies.
Core Business Areas
- Nucleic Acid Production: Manufactures modified nucleic acids for mRNA therapeutics and diagnostics. Includes CleanCap mRNA capping technology.
- Biologics Safety Testing: Provides testing services to ensure the safety and purity of biologics, vaccines, and cell and gene therapies.
- Protein Detection: Develops and manufactures immunoassay and protein detection products.
Leadership and Structure
Trey Martin serves as the Chief Executive Officer. The company operates with a functional organizational structure, divided into business units aligned with its core business areas.
Top Products and Market Share
Key Offerings
- CleanCap Reagents: Proprietary mRNA capping technology used in mRNA vaccine and therapeutic development. Competitors include TriLink BioTechnologies, Aldevron. Market share data is not publically available for this specific product.
- Cygnus Technologies: Provides process impurity testing. This is one of the products under Biologics Safety Testing. Competitors include Charles River Laboratories, Eurofins Scientific. Market share data is not publically available for this specific product.
Market Dynamics
Industry Overview
The life science reagents and services market is experiencing strong growth driven by advancements in biopharmaceuticals, genomics, and personalized medicine.
Positioning
Maravai Lifesciences is positioned as a leading provider of critical reagents and services, benefiting from its proprietary technologies and strong customer relationships.
Total Addressable Market (TAM)
The TAM for biopharmaceutical manufacturing and testing is estimated in the tens of billions of dollars. Maravai is well-positioned to capture a significant portion of this market through its specialized product offerings.
Upturn SWOT Analysis
Strengths
- Proprietary technologies (e.g., CleanCap)
- Strong customer relationships
- Diverse product portfolio
- Experienced management team
- High-quality products and services
Weaknesses
- Dependence on a few key products
- Competition from larger, more diversified companies
- Price competition
- Fluctuations in demand
Opportunities
- Expanding into new geographic markets
- Developing new products and services
- Acquiring complementary businesses
- Increasing adoption of mRNA technologies
- Growth in cell and gene therapy market
Threats
- Economic downturn
- Increased competition
- Technological obsolescence
- Regulatory changes
- Supply chain disruptions
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Merck KGaA (MRK.DE)
Competitive Landscape
Maravai competes with larger, more diversified companies. Maravai holds advantage in some specific technology such as CleanCap, but disadvantage in breadth of offering.
Major Acquisitions
Alphazyme
- Year: 2021
- Acquisition Price (USD millions): 175
- Strategic Rationale: Expansion of enzyme capabilities for mRNA manufacturing.
Growth Trajectory and Initiatives
Historical Growth: Maravai has experienced rapid growth in recent years, driven by the increasing demand for its products and services.
Future Projections: Future growth is projected to be moderate, driven by organic growth and strategic acquisitions.
Recent Initiatives: Focus on expanding its product portfolio and geographic reach, with more focus on its more consistent revenue generating lines of business after Covid demand has dropped.
Summary
Maravai Lifesciences is a key player in the life sciences reagents and services market, particularly known for its role in mRNA therapeutics. While the company has demonstrated rapid growth, its financials are highly variable due to the pandemic. The company is making progress, but it still needs to navigate competitive pressures and ensure a more diverse and resilient revenue stream, as well as the drop in overall revenue due to lower demand for reagents used in the production of COVID-19 vaccines.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Maravai Lifesciences Holdings Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2020-11-20 | CEO & Director Mr. Bernd Brust | ||
Sector Healthcare | Industry Biotechnology | Full time employees 580 | Website https://www.maravai.com |
Full time employees 580 | Website https://www.maravai.com | ||
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.